Neurology

Article	Citations
Neurologic manifestations in hospitalized patients with COVID-19	586
Miller Fisher syndrome and polyneuritis cranialis in COVID-19	567
Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions	345
Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19	294
International Consensus Guidance for Management of Myasthenia Gravis	270
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis	262
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy	254
Twenty-seven-year time trends in dementia incidence in Europe and the United States	226
COVID-19 presenting with ophthalmoparesis from cranial nerve palsy	225
COVID-19 and neuromuscular disorders	214
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy	208
A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City	197
Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid	186
Early postmortem brain MRI findings in COVID-19 non-survivors	185
Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy	171
Neurologic and neuroimaging findings in patients with COVID-19	170
Global prevalence and burden of HIV-associated neurocognitive disorder	169
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis	161
Frequency of Neurologic Manifestations in COVID-19	155
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome	153
Neurologic complications of coronavirus infections	147
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic	145
Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder	141
Different phenotypes in dermatomyositis associated with anti-MDA5 antibody	141
Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI	138

Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection	135
Neurofilament light as a biomarker in traumatic brain injury	134
COVID-19 is catalyzing the adoption of teleneurology	128
Incidence and Prevalence of Drug-Resistant Epilepsy	127
Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies	126
Healthy lifestyle and the risk of Alzheimer dementia	125
Global, Regional, and National Burden of Ischemic Stroke, 1990–2019	124
New onset neurologic events in people with COVID-19 in 3 regions in China	121
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS	120
Long-Haul COVID	120
Bilateral transient olfactory bulb edema during COVID-19–related anosmia	119
Practice advisory update summary: Patent foramen ovale and secondary stroke prevention	118
Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures	113
Neurologic Adverse Events of Immune Checkpoint Inhibitors	112
Keeping people with epilepsy safe during the COVID-19 pandemic	112
Rapid implementation of virtual neurology in response to the COVID-19 pandemic	108
Secondary Progressive Multiple Sclerosis	108
Neurologic manifestations in an infant with COVID-19	104
APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies	103
Analyzing 2,589 child neurology telehealth encounters necessitated by the COVID-19 pandemic	103
Serum neurofilament light as a biomarker in progressive multiple sclerosis	103
Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19	101
Criteria for defining interictal epileptiform discharges in EEG	101
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline	101
Generalized myoclonus in COVID-19	100
Brain arteriovenous malformations	98
Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease	98
Long-term safety, tolerability, and efficacy of fremanezumab in migraine	96
ATN classification and clinical progression in subjective cognitive decline	96
Stroke risk, phenotypes, and death in COVID-19	96
Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease	96
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease	95
Neurologic autoimmunity and immune checkpoint inhibitors	95
Association of epileptiform abnormalities and seizures in Alzheimer disease	94
Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies	92
Determination of death by neurologic criteria around the world	91
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis	91
Sex-driven modifiers of Alzheimer risk	90
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques	89
Initial high-efficacy disease-modifying therapy in multiple sclerosis	87
Five years of ocrelizumab in relapsing multiple sclerosis	87
Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke	87
Loss of smell in patients with COVID-19	87
Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy	87
Intracranial hemodynamic relationships in patients with cerebral small vessel disease	86
Global Impact of COVID-19 on Stroke Care and IV Thrombolysis	85
Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease	83
Worldwide Incidence and Prevalence of Neuromyelitis Optica	82
Incidence and case fatality rate of COVID-19 in patients with active epilepsy	82
Exosomal neurofilament light	82

Guillain-Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial	82
Thrombus NET content is associated with clinical outcome in stroke and myocardial infarction	82
Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease	82
Cranial neuropathies and COVID-19	81
Tobacco smoking and the risk of Parkinson disease	81
Probiotics for Constipation in Parkinson Disease	80
Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders	80
The implications of different approaches to define AT(N) in Alzheimer disease	79
Aerobic exercise improves cognition and cerebrovascular regulation in older adults	79
Preserving stroke care during the COVID-19 pandemic	78
Pearls & Oy-sters: Facial nerve palsy in COVID-19 infection	78
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis	77
Deep brain stimulation in early-stage Parkinson disease	76
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality	76
NfL as a biomarker for neurodegeneration and survival in Parkinson disease	76
Astrocyte Biomarkers in Alzheimer Disease	74
Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease	74
Diagnosis of prion diseases by RT-QuIC results in improved surveillance	74
Mortality in patients with psychogenic nonepileptic seizures	74
The 2013 clinical course descriptors for multiple sclerosis	73
Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET	73
Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age	73
Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease	71
Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort	71
Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program	71
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis	69
Severe childhood speech disorder	69
Effect of ApoE isoforms on mitochondria in Alzheimer disease	69
Neurologic Syndromes Predict Higher In-Hospital Mortality in COVID-19	69
Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19	69
CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms	68
Life Expectancy in Duchenne Muscular Dystrophy	68
The Economic Burden of Multiple Sclerosis in the United States	67
Cardiovascular risk factors and accelerated cognitive decline in midlife	66
Sex differences in the association between major risk factors and the risk of stroke in the UK Biobank cohort study	66
In Vivo Diagnosis of Synucleinopathies	66
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light	66
Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary	65
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary	64
On being a neurologist in Italy at the time of the COVID-19 outbreak	64
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis	63
Noncontrast CT markers of intracerebral hemorrhage expansion and poor outcome	63
Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis	63
Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder	63
Serum triglycerides in Alzheimer disease	62
Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation	62
Glial Fibrillary Acidic Protein Autoimmunity	62
Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays	62
Identification of GGC repeat expansion in the NOTCH2NLC gene in amyotrophic lateral sclerosis	61
Associations of Social Isolation and Loneliness With Later Dementia	61
β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies	61
Diabetes Mellitus, Glycemic Traits, and Cerebrovascular Disease	61
In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment	61
Real-life gait assessment in degenerative cerebellar ataxia	61
Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes	60
Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder	59
Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow)	59
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis	59
Multicenter prospective study on predictors of short-term outcome in disorders of consciousness	59
Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States	58
Ketamine to treat super-refractory status epilepticus	58
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis	58
Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs	57
Minor neuropsychological deficits in patients with subjective cognitive decline	57
Indications for Mechanical Thrombectomy for Acute Ischemic Stroke	57
Multitracer model for staging cortical amyloid deposition using PET imaging	57
Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease	57
Natalizumab in acute ischemic stroke (ACTION II)	57
Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease	56
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis	56
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration	56
Blood biomarkers of traumatic brain injury and cognitive impairment in older veterans	56
Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy	56
Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies	55
Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease	55
COVID-19–related encephalopathy responsive to high-dose glucocorticoids	54
Association of Dilated Perivascular Spaces With Cognitive Decline and Incident Dementia	54
Association of Collateral Status and Ischemic Core Growth in Patients With Acute Ischemic Stroke	54
Thalamus and focal to bilateral seizures	54
Effects of home-based telerehabilitation in patients with stroke	54

Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study	54
Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease	53
Applying Propensity Score Methods in Clinical Research in Neurology	53
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years	53
Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis	53
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease	52
Risk of Stroke in Cancer Survivors	52
The Ictal Signature of Thalamus and Basal Ganglia in Focal Epilepsy	52
Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies	52
Association of Cerebral Small Vessel Disease and Cognitive Decline After Intracerebral Hemorrhage	51
Long-term Dietary Flavonoid Intake and Subjective Cognitive Decline in US Men and Women	51
Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults	51
Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy	51
Broad phenotype of cysteine-altering NOTCH3 variants in UK Biobank	51
Functional gait disorders	51
Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration	51
Association of Sleep, Neuropsychological Performance, and Gray Matter Volume With Glymphatic Function in Community-Dwelling Older Adults	50
Central effects of erenumab in migraine patients	50
Neurogenic Dysphagia	50
Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease	50
Bi-directional association between epilepsy and dementia	50
Idiopathic distal sensory polyneuropathy	49
Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging	49
Diet pattern and prodromal features of Parkinson disease	48
Pharmacologic treatment and SUDEP risk	48
Endovascular treatment in older adults with acute ischemic stroke in the MR CLEAN Registry	48
Racial and Ethnic Disparities in Multiple Sclerosis Prevalence	48
Characterizing opioid use in a US population with migraine	48
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies	48
Longitudinal white-matter abnormalities in sports-related concussion	48
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension	47
Association of Age at Onset and First Symptoms With Disease Progression in Patients With Metachromatic Leukodystrophy	47
Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods	47
DNA Methylation and Protein Markers of Chronic Inflammation and Their Associations With Brain and Cognitive Aging	47
Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia	47
Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum	47
Neurologic deterioration in patients with acute ischemic stroke or transient ischemic attack	47
GBA variants in REM sleep behavior disorder	47
Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline	47
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis	47
7T Epilepsy Task Force Consensus Recommendations on the Use of 7T MRI in Clinical Practice	46
Preparing a neurology department for SARS-CoV-2 (COVID-19)	46
The clinical, histologic, and genotypic spectrum of SEPN1 -related myopathy	46
Multimodal longitudinal study of structural brain involvement in amyotrophic lateral sclerosis	46
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory	46
Global Burden, Risk Factor Analysis, and Prediction Study of Ischemic Stroke, 1990–2030	46
Sleep disorders in anti-NMDAR encephalitis	46
Diffusion-weighted MRI in transient global amnesia and its diagnostic implications	46
Sleep, major depressive disorder, and Alzheimer disease	46
Dementia in late-onset epilepsy	46
Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors	45
Autoimmune Encephalitis After SARS-CoV-2 Infection	45
Association of common genetic variants with brain microbleeds	45
Cerebral Amyloid Angiopathy–Related Transient Focal Neurologic Episodes	45
A Shortage of Neurologists – We Must Act Now	45
Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype	45
Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation	45
Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy	45
Blood Pressure After Endovascular Thrombectomy and Outcomes in Patients With Acute Ischemic Stroke	45
A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS	45
Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution	45
Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines	44
Analysis of the association of MPO and MMP-9 with stroke severity and outcome	44
Association of initial imaging modality and futile recanalization after thrombectomy	44
Vitamin D, smoking, EBV, and long-term cognitive performance in MS	43
Safety and efficacy of remote ischemic postconditioning after thrombolysis in patients with stroke	43
Acute symptomatic seizures in cerebral venous thrombosis	43
Muscle strength and motor function in adolescents and adults with spinal muscular atrophy	43
Abnormal development of cerebellar-striatal circuitry in Huntington disease	43
Dystonia and Tremor	43
CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET	42
Cell Therapy for Chronic TBI	42
Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies	42
Risk factors of Parkinson disease	42
Diet Inflammatory Index and Dementia Incidence	42
One-year sustained efficacy of erenumab in episodic migraine	42
Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms	42
Structural Brain Network Abnormalities and the Probability of Seizure Recurrence After Epilepsy Surgery	41
Location-specific risk factors for intracerebral hemorrhage	41
Early Neurologic Deterioration in Lacunar Stroke	41
Association of cerebrovascular reactivity and Alzheimer pathologic markers with cognitive performance	41
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis	41
Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline	40
High-Frequency Oscillations in Epilepsy	40
Prevention of benign paroxysmal positional vertigo with vitamin D supplementation	40
Diagnostic Yield of Lateral Decubitus Digital Subtraction Myelogram Stratified by Brain MRI Findings	40
Subjective Sleep Quality and Sleep Architecture in Patients With Migraine	40
Association of Metabolic Syndrome and Its Components With Risk of Stroke Recurrence and Mortality	40
Incidence, Prevalence, and Health Care Outcomes in Idiopathic Intracranial Hypertension	40
Encephalopathy and bilateral thalamic lesions in a child with MIS-C associated with COVID-19	40
Multicenter Validation of a Deep Learning Detection Algorithm for Focal Cortical Dysplasia	40
Association of fast ripples on intracranial EEG and outcomes after epilepsy surgery	40
Spatial-Temporal Patterns of β-Amyloid Accumulation	40
Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease	40
Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults	40